Typical TCA Dosing for Pain
For neuropathic pain, start with nortriptyline or desipramine 25 mg at bedtime, increase by 25 mg every 3-7 days as tolerated to a maximum of 150 mg/day, and continue for 6-8 weeks with at least 2 weeks at the maximum tolerated dose before declaring treatment failure. 1
Starting Dose and Agent Selection
- Begin with secondary-amine TCAs (nortriptyline or desipramine) rather than tertiary-amine TCAs (amitriptyline) 1
- Start at 25 mg at bedtime 1
- Secondary amines have better tolerability profiles, though amitriptyline remains commonly prescribed (used in 58-79% of cases in practice) 2, 3
Important Caveat on Agent Choice
While guidelines recommend secondary amines first, research shows amitriptyline and nortriptyline are equivalent for overall adverse effects and discontinuation rates, with similar efficacy (23-26% pain reduction) 4. The main difference: amitriptyline causes more weight gain, while nortriptyline causes more dry mouth 4.
Titration Schedule
- Increase by 25 mg every 3-7 days as tolerated 1
- Target dose: 150 mg/day maximum for pain management 1
- If blood concentration of active medication plus metabolite is <100 ng/mL, you may continue cautious titration beyond 150 mg 1
Real-World Dosing Pattern
Be aware that in clinical practice, most patients (73%) receive subtherapeutic low doses (≤50 mg amitriptyline equivalent), with only 12% receiving full doses (≥150 mg equivalent) 3. This represents a common pitfall—don't stop at low doses if the patient tolerates the medication but has inadequate response.
Duration of Adequate Trial
6-8 weeks total, with at least 2 weeks at the maximum tolerated dose 1
This extended trial period is critical because:
- Initial titration takes 3-6 weeks
- You need 2 additional weeks at target dose to assess efficacy
- Premature discontinuation is a common reason for treatment failure
Cardiovascular Monitoring Considerations
A critical safety concern: 41% of older patients prescribed TCAs have cardiovascular conditions that may render their use potentially inappropriate 2. Additionally:
- Low-dose TCAs (0.15-0.34 DDD) paradoxically increase cardiovascular event risk (HR 1.37), particularly with nortriptyline (HR 2.11) 5
- Traditional doses (≥0.34 DDD) increase ischemic stroke risk (HR 2.08) 5
- Monitor cardiovascular status closely and avoid long-term accumulation of low doses that increase cumulative cardiovascular risk 5
Role in Multimodal Pain Management
TCAs should be used as part of a multimodal strategy for chronic pain, particularly neuropathic pain 6. They work by:
- Blocking N-type calcium channels (CaV2.2) 7
- Suppressing the noradrenergic descending inhibitory system 8
- Providing analgesic effects independent of antidepressant properties 8
Expected Discontinuation Rates
26-37% of patients will discontinue TCAs due to either inefficacy or adverse effects 4. This high discontinuation rate underscores the importance of:
- Proper patient selection
- Slow titration to minimize side effects
- Setting realistic expectations about tolerability